However, as MASLD is a slow progressive disease in which immune signaling plays an important role, one may expect IL1R1 signaling to have different effects compared to acute inflammatory liver injury, potentially explaining these opposing results. This evidence concerns the gene IL1R1 and metabolic dysfunction-associated steatotic liver disease.